An open-label, randomized, three-parallel-group study on pharmacodynamic effects of 8-week QD treatment with lixisenatide compared to liraglutide in patients with type 2 diabetes not adequately controlled with insulin glargine with or without metformin.
Latest Information Update: 03 Oct 2021
Price :
$35 *
At a glance
- Drugs Lixisenatide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 17 Sep 2014 Primary endpoint has been met (change from baseline for area under the plasma glucose concentration time profile), according to results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 15 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.